ERBB2 and prostate carcinoma: In this commentary, we discussed two patients with metastatic prostate cancer who were classified as HER2 IHC 3+ using our prostate cancer-specific scoring system and who demonstrated meaningful clinical responses and responded to treatment with T-DXd.